Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?

Documenti analoghi

• Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
  di: Jessica D. Lee, et al.
  Pubblicazione: (2025)
• Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
  di: Jessica D. Lee, et al.
  Pubblicazione: (2025)
• Editorial: Allostatic Load and Inflammatory Bowel Disease
  di: Jeli Mendoza, et al.
  Pubblicazione: (2024)
• Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
  di: Matthew D. Coates, et al.
  Pubblicazione: (2025)
• Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
  di: Marco Vincenzo Lenti, et al.
  Pubblicazione: (2025)